Company / Revenue per Share
ANI Pharmaceuticals, Inc. Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$41.85
FY2025
5-year range
$17.16 / $41.85
FY2021-FY2025
Trend
+10.8%
vs FY2024
Sector context
#10 of 154
Health Care
What the data says
Among 154 Health Care companies, ANI Pharmaceuticals, Inc. is in the top 6% for revenue per share. Revenue per Share has increased for 4 consecutive years, from $17.16 in FY2021 to $41.85 in FY2025.
Based on SEC 10-K filings.
41.85 in FY2025 with a 5-year CAGR of +19.2%. Top quartile in the Health Care sector.
Improved from $26.76 to $41.85 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +29.1%
- 5-Year CAGR
- +19.2%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 154This company $41.85 Sector average $15.09
▼
+177.3% above sector average
Key checks
Key Insights
- ANI Pharmaceuticals, Inc.'s revenue per share has grown for 4 consecutive years.
- In FY2025, revenue per share increased 10.8% year-over-year.
- Ranks #10 out of 154 companies in the Health Care sector.
- Lowest revenue per share in the period was in FY2019.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $41.85 | +10.8% |
| FY2024 | $37.78 | +41.2% |
| FY2023 | $26.76 | +37.5% |
| FY2022 | $19.46 | +13.4% |
| FY2021 | $17.16 | -1.5% |
| FY2020 | $17.43 | +280.5% |
| FY2019 | $4.58 | -73.3% |
| FY2018 | $17.12 | +11.9% |
| FY2017 | $15.30 | +37.7% |
| FY2016 | $11.11 | -99.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026